Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
复制标题
DOI：
10.2337/dci22-0034
复制
发表时间：
2022-11-01
期刊：
影响因子：
16.2
通讯作者：
Buse, John B.
中科院分区：
文献类型：
--
作者：
Davies, Melanie J.;Aroda, Vanita R.;Buse, John B.
美国糖尿病协会和欧洲糖尿病研究协会召集了一个小组，更新之前关于成人2型糖尿病高血糖管理的共识声明，这些声明发表于2006年，最后一次更新是在2019年。目标受众是在美国和欧洲提供糖尿病护理的专业医疗团队的所有成员。对2018年以来的出版物进行了系统审查，提出了新的建议。这些措施包括对健康的社会决定因素、医疗保健系统和包括睡眠在内的体力活动行为的额外关注。作为糖尿病整体管理方法的一部分，体重管理得到了更大的重视。涉及钠-葡萄糖共转运体2抑制剂和胰高血糖素样肽1受体激动剂的心血管和肾脏结果试验的结果，包括对亚组的评估，为糖尿病患者心脏肾脏疾病高危人群的心肾保护提供了更广泛的建议。在总结了协商一致的建议之后，提供了执行方面的实用技巧。
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.